nivolumabipilimumabpembrolizumabtremelimumabatezolizumabavelumabdurvalumabcemiplimabICIzoledronate+1 more
…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …
36articles mentioning drugs
113drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Durvalumab ×
Durvalumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Durvalumab
36 articles · page 3 of 3vilastobartatezolizumabpembrolizumab
…rable (figure 2). Consistent with the tumor-activated design of vilastobart, treatment was generally well-tolerated: overall (n=44), 11 pat…
nivolumabpembrolizumabatezolizumabipilimumabtremelimumabdurvalumabavelumablenvatinibTACEMelanoma+3 more
…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…
pembrolizumabnivolumabatezolizumabcemiplimabavelumabdurvalumabdocetaxelsolid tumorsClinicalTrials.govN Engl J Med+1 more
…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…
nivolumabpembrolizumabipilimumabatezolizumabavelumabcemiplimabdurvalumabdostarlimabrelatlimabBurkitt’s Lymphoma+1 more
…114 male and 50 female (unspecified 17). The ICIs involved were nivolumab (n=68), pembrolizumab (n=51), ipilimumab (n=35), atezolizumab (…
pembrolizumabdurvalumabnivolumabatezolizumabTNBCtriple-negative breast cancerTriNetX
… TNBC (ER-/PR-/HER2-) who received at least one dose of an ICI (pembrolizumab, atezolizumab, nivolumab, or durvalumab) between 2014 and 2025.…
nivolumabdurvalumabtislelizumabatezolizumabpembrolizumabnon-small cell lung cancermelanomapneumonitisImmune checkpoint inhibitorsFDA-approved
…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…
PembrolizumabDurvalumabNivolumablung cancerTranslational Immunology LaboratoryUniversity of SydneyThe University of Sydney Ethics Board
…=33 non-small cell lung cancer and n=2 small cell) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
durvalumabatezolizumabtoripalimabnivolumabcemiplimabipilimumabNorthwestern Memorial Hospitalbilateral non-small cell lung cancerCOPDcolorectal cancer+4 more
…s (n=7, 47%), nivolumab/ipilimumab (n=3, 20%), atezolizumab and durvalumab (n=2 each, 13%), and cemiplimab and toripalimab (n=1 each, 7%) …
PembrolizumabDurvalumabNivolumablung cancerUniversity of SydneyThe Translational Immunology Laboratory
…9 non-small cell and n=2 small cell, respectively) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…
atezolizumabpembrolizumabdurvalumabmetastatic urothelial carcinomaEmory University
…ith multiple lines of immunotherapy (durvalumab, pembrolizumab, atezolizumab).Methods In our single-center retrospective cohort (n=57), prim…
lenvatinibatezolizumab-bevacizumabdurvalumabtremelimumabHepatocellular carcinomaRimini et alAhn et alimmunotherapyHCCsystemic therapies
… the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the advent of immunoth…